Tumor-Related Molecular Mechanisms of Oxaliplatin Resistance

被引：285

作者：

Martinez-Balibrea, Eva ^{[1
,2
]}

Martinez-Cardus, Anna ^{[3
]}

Gines, Alba ^{[2
]}

Ruiz de Porras, Vicenc ^{[2
]}

Moutinho, Catia ^{[3
]}

Layos, Laura ^{[1
]}

Luis Manzano, Jose ^{[1
]}

Buges, Cristina

Bystrup, Sara ^{[2
]}

Esteller, Manel ^{[3
,4
,5
]}

Abad, Albert ^{[1
,2
,6
]}

机构：

[1] Hosp Badalona Germans Trias & Pujol, Med Oncol Serv, ICO, Barcelona 08916, Spain

[2] Inst Germans Trias & Pujol Fdn IGTP, Hlth Sci Res Inst, Badalona, Catalonia, Spain

[3] Bellvitge Biomed Res Inst IDIBELL, PEBC, Barcelona, Catalonia, Spain

[4] Univ Barcelona, Sch Med, Dept Physiol Sci 2, Barcelona, Catalonia, Spain

[5] ICREA, Barcelona, Catalonia, Spain

[6] Hosp CIMA Sanitas, Oncol Unit, Barcelona, Catalonia, Spain

来源：

MOLECULAR CANCER THERAPEUTICS | 2015年 / 14卷 / 08期

关键词：

COLORECTAL-CANCER PATIENTS; PLATINUM-BASED CHEMOTHERAPY; COMPLEMENTATION GROUP 1; BASE EXCISION-REPAIR; FACTOR-KAPPA-B; CELL-LINE; GENETIC POLYMORPHISMS; THYMIDYLATE SYNTHASE; ACQUIRED-RESISTANCE; FOLFOX-4; TREATMENT;

D O I：

10.1158/1535-7163.MCT-14-0636

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Oxaliplatin was the first platinum drug with proven activity against colorectal tumors, becoming a standard in the management of this malignancy. It is also considered for the treatment of pancreatic and gastric cancers. However, a major reason for treatment failure still is the existence of tumor intrinsic or acquired resistance. Consequently, it is important to understand the molecular mechanisms underlying the appearance of this phenomenon to find ways of circumventing it and to improve and optimize treatments. This review will be focused on recent discoveries about oxaliplatin tumor-related resistance mechanisms, including alterations in transport, detoxification, DNA damage response and repair, cell death (apoptotic and nonapoptotic), and epigenetic mechanisms.

引用

页码：1767 / 1776

页数：10

共 104 条

[1] Sec61β Controls Sensitivity to Platinum-Containing Chemotherapeutic Agents through Modulation of the Copper-Transporting ATPase ATP7A [J].

Abada, Paolo B. ;

Larson, Christopher A. ;

Manorek, Gerald ;

Adams, Preston ;

Howell, Stephen B. .

MOLECULAR PHARMACOLOGY, 2012, 82 (03) :510-520

[2] Platinum-DNA Interactions and Subsequent Cellular Processes Controlling Sensitivity to Anticancer Platinum Complexes [J].

Ahmad, Saeed .

CHEMISTRY & BIODIVERSITY, 2010, 7 (03) :543-566

[3] The Role of MMP7 and Its Cross-Talk with the FAS/FASL System during the Acquisition of Chemoresistance to Oxaliplatin [J].

Almendro, Vanessa ;

Ametller, Elisabet ;

Garcia-Recio, Susana ;

Collazo, Olga ;

Casas, Ignasi ;

Auge, Josep M. ;

Maurel, Joan ;

Gascon, Pedro .

PLOS ONE, 2009, 4 (03)

[4] Tumor promoting effects of CD95 signaling in chemoresistant cells [J].

Ametller, Elisabet ;

Garcia-Recio, Susana ;

Costamagna, Domizziana ;

Mayordomo, Cristina ;

Fernandez-Nogueira, Patricia ;

Carbo, Neus ;

Maria Pastor-Arroyo, Eva ;

Gascon, Pedro ;

Almendro, Vanessa .

MOLECULAR CANCER, 2010, 9

[5] Cellular determinants of oxaliplatin sensitivity in colon cancer cell lines [J].

Arnould, S ;

Hennebelle, I ;

Canal, P ;

Bugat, R ;

Guichard, S .

EUROPEAN JOURNAL OF CANCER, 2003, 39 (01) :112-119

[6]

Ban N, 1996, CANCER RES, V56, P3577

[7] Treatment Patterns and Clinical Outcomes in Patients With Metastatic Colorectal Cancer Initially Treated with FOLFOX-Bevacizumab or FOLFIRI-Bevacizumab: Results From ARIES, a Bevacizumab Observational Cohort Study [J].

Bendell, Johanna C. ;

Beikaii-Saab, Tanios S. ;

Cohn, Allen L. ;

Hurwitz, Herbert I. ;

Kozloff, Mark ;

Tezcan, Haluk ;

Roach, Nancy ;

Mun, Yong ;

Fish, Susan ;

Flick, E. Dawn ;

Dalal, Darshan ;

Grothey, Axel .

ONCOLOGIST, 2012, 17 (12) :1486-1495

[8] Increased levels and defective glycosylation of MRPs in ovarian carcinoma cells resistant to oxaliplatin [J].

Beretta, Giovanni Luca ;

Benedetti, Valentina ;

Cossa, Giacomo ;

Assaraf, Yehuda G. A. ;

Bram, Eran ;

Gatti, Laura ;

Corna, Elisabetta ;

Carenini, Nives ;

Colangelo, Donato ;

Howell, Stephen B. ;

Zunino, Franco ;

Perego, Paola .

BIOCHEMICAL PHARMACOLOGY, 2010, 79 (08) :1108-1117

[9] A Review of Excision Repair Cross-complementation Group 1 in Colorectal Cancer [J].

Bohanes, Pierre ;

LaBonte, Melissa J. ;

Lenz, Heinz-Josef .

CLINICAL COLORECTAL CANCER, 2011, 10 (03) :157-164

[10] Characterization of p53 wild-type and null isogenic colorectal cancer cell lines resistant to 5-fluorouracil, oxaliplatin, and irinotecan [J].

Boyer, J ;

McLean, EG ;

Aroori, S ;

Wilson, P ;

McCulla, A ;

Carey, PD ;

Longley, DB ;

Johnston, PG .

CLINICAL CANCER RESEARCH, 2004, 10 (06) :2158-2167

← 1 2 3 4 5 6 7 8 9 10 →